Global Pretomanid Tablets Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Pretomanid Tablets market size was valued at US$ 185 million in 2025 and is forecast to a readjusted size of US$ 400 million by 2032 with a CAGR of 10.0% during review period.
Pretomanid tablets are a novel nitroimidazopyran anti-tuberculosis drug with potent bactericidal activity against multidrug-resistant tuberculosis. It exerts a bactericidal effect by inhibiting the synthesis of proteins and cell walls of Mycobacterium tuberculosis. As a core drug in the fully oral, long-course anti-tuberculosis regimen, it is often combined with bedaquiline and linezolid to form the BPaL regimen, for the treatment of extensively drug-resistant pulmonary tuberculosis or multidrug-resistant pulmonary tuberculosis with intolerance or ineffective conventional treatment. Featuring favorable oral absorption, strong tissue penetration and controllable safety, it is a core therapeutic drug for drug-resistant tuberculosis recommended by WHO, which significantly improves the cure rate of refractory tuberculosis.In 2025, global Pretomanid tablets production reached approximately 1,200,000 bottles
As an innovative drug in the global anti-tuberculosis field, Pretomanid tablets are strategically positioned and developed based on the clinical demand for drug-resistant tuberculosis and the construction of public health systems. As a core component of the fully oral, short-course BPaL (or BPaLM) combination regimen, Pretomanid is mainly indicated for multidrug-resistant and extensively drug-resistant tuberculosis. With superior efficacy and safety compared with traditional regimens, it has become a core drug recommended by the World Health Organization for drug-resistant tuberculosis, driving the global shift from long-course, high-adverse-effect tuberculosis treatments to short-course, high-compliance regimens.
In terms of market structure, the global market features a diversified supply pattern of innovator and generic drugs. The originator product developed by TB Alliance expands coverage in high-burden countries and low- and middle-income markets through multi-manufacturer authorization. Meanwhile, generic drugs qualified by WHO prequalification significantly improve drug accessibility via international public health procurement and regional supply chains, forming a supply system dominated by public health programs. In China, the approval and inclusion of Pretomanid in the medical insurance catalogue have substantially improved diagnosis and treatment accessibility and reduced patient burden, advancing domestic drug-resistant tuberculosis prevention and control into a new stage of highly effective and inclusive treatment.
The core drivers of market growth lie in three aspects: first, the persistent global incidence of drug-resistant tuberculosis sustains strong demand for new and effective treatment regimens; second, countries gradually incorporate BPaL-based short-course regimens into national tuberculosis programs, accelerating clinical adoption and policy implementation; third, price optimization and multi-manufacturer deployment balance drug value and healthcare system costs, expanding accessibility. Meanwhile, market development faces challenges such as regional disparities in medical resources, standardized management of treatment regimens, and improvement of drug resistance monitoring systems. Further consolidation of its core position in drug-resistant tuberculosis therapy relies on public health cooperation, improved cross-regional supply chains, and continuous accumulation of real-world data.
This report is a detailed and comprehensive analysis for global Pretomanid Tablets market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Pretomanid Tablets market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Pretomanid Tablets market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Pretomanid Tablets market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Pretomanid Tablets market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Pretomanid Tablets
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Pretomanid Tablets market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include TB Alliance, Macleods Pharmaceuticals, Lupin Limited, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Pretomanid Tablets market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
26 tablets/box
182 tablets/bottle
Market segment by Packaging
Bottle
Box
Market segment by Storage
Protect From Light
Protect From Moisture
Market segment by Production Technology
Innovator
Generic
Market segment by Application
Multidrug-Resistant Pulmonary Tuberculosis (MDR-TB)
Extensively Drug-Resistant Pulmonary Tuberculosis (XDR-TB)
Others
Major players covered
TB Alliance
Macleods Pharmaceuticals
Lupin Limited
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Pretomanid Tablets product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Pretomanid Tablets, with price, sales quantity, revenue, and global market share of Pretomanid Tablets from 2021 to 2026.
Chapter 3, the Pretomanid Tablets competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Pretomanid Tablets breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Pretomanid Tablets market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Pretomanid Tablets.
Chapter 14 and 15, to describe Pretomanid Tablets sales channel, distributors, customers, research findings and conclusion.